Oncolytics Biotech Inc. (TSE:ONC) Senior Officer Kirk Look Purchases 12,800 Shares

Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) Senior Officer Kirk Look purchased 12,800 shares of the stock in a transaction that occurred on Tuesday, July 15th. The shares were acquired at an average cost of C$1.60 per share, with a total value of C$20,517.12.

Oncolytics Biotech Stock Down 2.8%

TSE:ONC traded down C$0.05 on Friday, reaching C$1.73. 245,934 shares of the stock traded hands, compared to its average volume of 147,357. The company has a market capitalization of C$133.34 million, a price-to-earnings ratio of -4.82 and a beta of 1.35. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75. Oncolytics Biotech Inc. has a 12 month low of C$0.44 and a 12 month high of C$2.08. The company's fifty day simple moving average is C$0.92 and its 200 day simple moving average is C$0.95.

Wall Street Analyst Weigh In

Separately, Jones Trading cut shares of Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.